ライフサイエンスコーパス: polypharmacy

1 oximately, 46.6% of participants experienced polypharmacy.

2 history, myocardial infarction history, and polypharmacy.

3 omising approach to addressing the burden of polypharmacy.

4 ularly for cases of treatment resistance and polypharmacy.

5 RD is correlated with a higher prevalence of polypharmacy.

6 taking, thus offering a richer assessment of polypharmacy.

7 led prescriptions consistent with CNS-active polypharmacy.

8 ife) seizures that are usually refractory to polypharmacy.

9 ctivities in young mice, compared to control/polypharmacy.

10 ue to their prevalence of multimorbidity and polypharmacy.

11 34 surgical patients, 68.1% met criteria for polypharmacy.

12 n by a person with functional impairment and polypharmacy.

13 imposes an economic cost and contributes to polypharmacy.

14 impaired timed up and go test, and 40% with polypharmacy.

15 often experience multimorbidity and require polypharmacy.

16 t number of medications (1-2) and absence of polypharmacy.

17 mon, pre-morbid and co-morbid conditions, or polypharmacy.

18 among older patients with multimorbidity and polypharmacy.

19 two matched cohorts: those with and without polypharmacy.

20 cture, chronic kidney disease, dementia, and polypharmacy.

21 th problems when compared with antipsychotic polypharmacy.

22 appropriate medications in older adults with polypharmacy.

23 al for toxicity, drug-drug interactions, and polypharmacy.

24 in the context of multiple co-morbidity and polypharmacy.

25 dities and drug-drug interactions in case of polypharmacy.

26 tors, including age, sex, comorbidities, and polypharmacy.

27 specially in elderly patients and those with polypharmacy.

28 an antiretroviral regimen, increase risk for polypharmacy.

29 scontinuation than those assigned to stay on polypharmacy.

30 inuations entailed returning to the original polypharmacy.

31 tic demonstration of rational anticonvulsant polypharmacy.

32 especially in the context of comorbidity and polypharmacy.

33 h metabolic syndrome may be affected more by polypharmacy.

34 = 161 412) met the criterion for CNS-active polypharmacy (32 139 610 polypharmacy-days of exposure).

35 ohort, 68% received 1 co-medication, 14% had polypharmacy ( 5 co-medications) and 29% had 1 PDDI.

36 Of those with CNS-active polypharmacy, 57.8% were exposed for longer than 180 day

37 e datasets and improving signal detection in polypharmacy, addressing a significant challenge in phar

38 on analyses constipation was associated with polypharmacy (adjusted PR: 2.99, 95% CI: 1.18-7.57, p =

39 mmon in older adults with multimorbidity and polypharmacy admitted to hospital and was reduced throug

40 : 1.77; CI: 1.45, 2.15) were associated with polypharmacy among GERD patients.

41 ng cascades are an underrecognized driver of polypharmacy among older adults (aged >=65 years).

42 es that can mitigate the negative effects of polypharmacy among older adults with HF.

43 uncontrolled diabetes and widespread use of polypharmacy among patients.

44 of non-communicable diseases, and resulting polypharmacy among people living with HIV, there are pot

45 sessed the prevalence and clinical impact of polypharmacy among PWH.

46 Excluding ART, 24% of study participants had polypharmacy and 4% had hyperpolypharmacy.

47 e infection was observed in 6% of those with polypharmacy and 4% of those without polypharmacy (p < 0

48 h, syncope in the elderly often results from polypharmacy and abnormal physiologic responses to daily

49 hout statins, although statin users had more polypharmacy and circulatory illnesses than non-users.

50 ith less residual confounding due to minimal polypharmacy and comorbidity in children.

51 We developed a multidimensional measure of polypharmacy and compared with standard cut-offs.

52 drug-drug similarities, assess the degree of polypharmacy and conclude that drug effects are distribu

53 timated the prevalence of multimorbidity and polypharmacy and described algorithms devised for use ac

54 increased focus on identifying and managing polypharmacy and hyperpolypharmacy in PWH.

55 stics of US youths treated with psychotropic polypharmacy and in the psychotropic classes used in com

56 valence, associated factors, and patterns of polypharmacy and medication use among GERD patients in s

57 were in line with the primary comparison of polypharmacy and monotherapy within the same individual.

58 is recommended for some older patients with polypharmacy and multimorbidity when the benefits of con

59 s between monotherapy and no use and between polypharmacy and no use were in line with the primary co

60 y and safety challenges, including increased polypharmacy and patient diversity, stress the limits of

61 s may be large, given the high prevalence of polypharmacy and PIMs in community-dwelling older adults

62 tient safety and quality of care by reducing polypharmacy and potentially inappropriate medications (

63 udy aimed to examine the association between polypharmacy and the risk of hospitalization and mortali

64 lable deprescribing interventions may reduce polypharmacy and the use of potentially inappropriate me

65 a growing concern in Western societies where polypharmacy and ultraprocessed foods and beverages are

66 djustment for immune-mediated conditions and polypharmacy and when compared with unaffected siblings.

67 eatment challenges, including comorbidities, polypharmacy, and a higher risk for infections (eg, herp

68 to drug-drug interactions, the emergence of polypharmacy, and additional preventable spending to alr

69 spite the presence of greater comorbidities, polypharmacy, and altered pharmacokinetics in this age g

70 omplicated by the presence of comorbidities, polypharmacy, and concomitant functional impairment, but

71 n of low-value prescribing practices, reduce polypharmacy, and enable older adults to receive high-va

72 omorbid medical illnesses, social isolation, polypharmacy, and factors associated with end-of-life ca

73 ion co-occurs with other chronic conditions, polypharmacy, and geriatric syndromes such as frailty.

74 eprivation, ASCVD risk factors, comorbidity, polypharmacy, and healthcare usage were accounted for (f

75 en living with multimorbidity and exposed to polypharmacy, and many experience medication-related pro

76 y, impaired cognitive and physical function, polypharmacy, and other complexities of care, can underm

77 eviewing evidence-based approaches to reduce polypharmacy, and outlining the potential benefits of de

78 expected adverse drug reactions, unnecessary polypharmacy, and the need to align medications with goa

79 MCI, clinicians should consider depression, polypharmacy, and uncontrolled cardiovascular risk facto

80 igh dose (>=1.1 DDDs per day); antipsychotic polypharmacy; and antipsychotics categorized according t

81 cluding EPS (AOR = 3.95, 95% CI: 1.84-8.48), polypharmacy (AOR = 2.15, 95% CI: 1.56-2.96), substance

82 extremely common, but evidence regarding all polypharmacy approaches for schizophrenia from randomize

83 e on evidence regarding the effectiveness of polypharmacy approaches.

84 ddressing medication initiation and managing polypharmacy are central to HF transitional care.

85 The resulting problems of polypharmacy are increase in side effects, drug-drug int

86 Defining polypharmacy as taking >=10 medications might be more id

87 With increasing comorbidity and polypharmacy as well as an ageing population, cardiovasc

88 diovascular disease burden and high level of polypharmacy, as well as recurrent exposure to electroly

89 escribing interventions in older adults with polypharmacy, as well as reports on ongoing trials, guid

90 imitations, malnutrition, comorbidities, and polypharmacy, as well as social support.

91 These findings highlight that in mice, some polypharmacy-associated behavioral changes are greater i

92 hospitalization was significantly lower for polypharmacy at the highest total dosage category (-18%,

93 %), general aversion to medications (19.1%), polypharmacy burden (17.1%) and fear of adverse reaction

94 were more likely to express a concern about polypharmacy burden (OR 1.09; 95% CI 1.005-1.18).

95 st missed opportunities to reduce burdensome polypharmacy by deprescribing long-term medications with

96 dney disease-related complications, reducing polypharmacy by deprescription, personalizing dialysis p

97 The PR of experiencing Polypharmacy by GERD patients compared to non-GERD patie

98 Polypharmacy classes were compared to standard cut-offs

99 Our evaluation demonstrates the value of a polypharmacy clinic in improving medication list accurac

100 the design and the pre-post evaluation of a polypharmacy clinic.

101 iatric conditions (including multimorbidity, polypharmacy, cognitive decline and delirium, and frailt

102 d by the context of multimorbidity, frailty, polypharmacy, cognitive dysfunction, functional decline,

103 dverse events, due to the multimorbidity and polypharmacy, common in elderly patients.

104 sought to study the safety of antipsychotic polypharmacy compared with monotherapy in specific dosag

105 eased hospitalizations, healthcare costs and polypharmacy complications.

106 Aging, polypharmacy (concurrent use of >= 5 medications), and f

107 edications (range: 17-33 medications) at the polypharmacy consult visit, 2.6 medications were depresc

108 were also more likely to report weight loss, polypharmacy, consumption of a special diet, and functio

109 asso regression for analyzing rare events in polypharmacy contexts, focusing on severe ADRs such as f

110 generation antipsychotics, and antipsychotic polypharmacy continued the same antipsychotic therapy fo

111 Polypharmacy continues to be a major and poorly understo

112 ative risk, suggesting that individuals with polypharmacy could benefit from postural BP monitoring.

113 cancer, we expect that greater attention to polypharmacy could lead to improvements in adverse drug

114 Ninety-two percent of polypharmacy-days included an antidepressant, 47.1% incl

115 rion for CNS-active polypharmacy (32 139 610 polypharmacy-days of exposure).

116 NS-active polypharmacy, the median number of polypharmacy-days was 193 (IQR, 88-315 polypharmacy-days

117 ntiepileptic, and an antipsychotic (12.9% of polypharmacy-days).

118 er of polypharmacy-days was 193 (IQR, 88-315 polypharmacy-days).

119 medication and was associated with 33.0% of polypharmacy-days.

120 after 4 weeks of treatment, high DBI (HDBI) polypharmacy decreased exploration (reduced mean gait sp

121 We assessed the relationship between polypharmacy (defined as the use of 5 or more prescripti

122 use (DID, -0.4%; 95% CI -0.7% to -0.01%) and polypharmacy (DID, -0.3%; 95% CI, -0.4% to -0.1%).

123 In this study of patients receiving polypharmacy, discontinuing statins while maintaining ot

124 Among those who met the criterion for polypharmacy, duration of exposure, number of distinct m

125 and less than 10 medications, and excessive polypharmacy (EPP) was defined as 10 or more medications

126 licensing trials, the increasing problems of polypharmacy (especially in the elderly), the lack of tr

127 ations and healthcare utilization related to polypharmacy following spinal surgery for degenerative l

128 and concomitant geriatric conditions such as polypharmacy, frailty, and cognitive dysfunction-a combi

129 iovascular perspectives with multimorbidity, polypharmacy, frailty, cognitive decline, and other clin

130 , during which drug-drug interactions due to polypharmacy further enhance the risk of adverse effects

131 r the polypharmacy group and 17% for the non-polypharmacy group (p < 0.0001).

132 one complication was observed in 24% for the polypharmacy group and 17% for the non-polypharmacy grou

133 e monotherapy group lost weight, whereas the polypharmacy group gained weight.

134 Two years postoperatively, the polypharmacy group had tripled overall healthcare utiliz

135 hort, 68% received > 1 comedication, 14% had polypharmacy (> 5 comedications) and 29% had > 1 PDDI.

136 , 5-6, 7-8, 9-10, and >= 11) and presence of polypharmacy (>= 5 prescription drugs per day).

137 diseases), were aged 70 years or older, had polypharmacy (>=5 long-term medications), and were admit

138 Participants with polypharmacy had a higher risk of slow gait speed (odds

139 Those with CNS-active polypharmacy had a median age of 79.4 years (IQR, 74.0-8

140 ist-led clinics focused on broader issues of polypharmacy have the potential to lead to better outcom

141 idone LAI (hazard ratio=0.76), antipsychotic polypharmacy (hazard ratio=0.77), and risperidone LAI (h

142 pes of chronic pain, comorbidities, frailty, polypharmacy, healthcare utilization, use of nonopioid m

143 ted approach to manage their multimorbidity, polypharmacy, high rates of adverse outcomes, mental hea

144 MetS patients are strongly exposed to polypharmacy; however, the number of pharmacological com

145 at that patients should be free to return to polypharmacy if an adequate trial on antipsychotic monot

146 ary outcome was the prevalence of CNS-active polypharmacy in 2018, defined as exposure to 3 or more m

147 s Review examines the existing literature on polypharmacy in advanced cancer and end-of-life settings

148 Given the complex polypharmacy in HF treatment, cognitive deficits may be

149 ic time window and the potential of reducing polypharmacy in mTBI treatment.

150 Polypharmacy in older adults increases the risk of adver

151 at heterogeneity in interventions addressing polypharmacy in older adults.

152 Polypharmacy in older patients can be minimized by using

153 In view of the apparent burden of polypharmacy in patients with advanced cancer, we expect

154 strategy to control hypertension and related polypharmacy in subjects with obesity.

155 Our study revealed a high degree of polypharmacy in the acute stages of spinal cord injury,

156 ntial to reduce the problems associated with polypharmacy in the context of MetS.

157 result from polypharmacy, real-world data on polypharmacy in the setting of heart failure (HF) are li

158 e identified based on multiple indicators of polypharmacy, including quantity, temporality and risk p

159 , because increasing age, comorbidities, and polypharmacy increase the risk of both thrombosis and bl

160 The prevalence of taking >=10 medications (polypharmacy) increased over the study period.

161 re has been a recent significant increase in polypharmacy involving antidepressant and antipsychotic

162 Polypharmacy is a growing and major public health issue,

163 Polypharmacy is a major health concern among older adult

164 acology is a common feature of many ASDs and polypharmacy is a usual practice to treat epileptic pati

165 Polypharmacy is a well known problem in elderly patients

166 Polypharmacy is associated with mortality, falls, hospit

167 Polypharmacy is common among patients with CKD, but litt

168 As a result, polypharmacy is common and increases the risk of drug-dr

169 Polypharmacy is common both at admission and hospital di

170 Polypharmacy is common in older adults and is associated

171 Polypharmacy is common in patients with nonalcoholic fat

172 Psychotropic medication polypharmacy is common in psychiatric outpatient setting

173 Polypharmacy is common in the treatment of refractory bi

174 Polypharmacy is commonly defined based on the number of

175 Epidemiology studies have demonstrated that polypharmacy is extremely common, but evidence regarding

176 knowledge of the age/sex-specific effects of polypharmacy is limited, particularly on daily physical

177 es, specifically poor compliance to lifelong polypharmacy, lifestyle modifications, and physician ine

178 ring of the Adult Comorbidity Evaluation 27, polypharmacy, Malnutrition Universal Screening Tool, Act

179 e providers in HIV, ageing, comorbidity, and polypharmacy management.

180 older adults with frailty syndrome, reducing polypharmacy may have utility as a safety-promoting trea

181 atients, central nervous system (CNS)-active polypharmacy may increase the risk for impaired cognitio

182 ll cohort inclued 29 047 patients exposed to polypharmacy (mean [SD] age, 76.5 [6.5] years; 18 257 [6

183 After HDBI polypharmacy, mean gait speed consistently decreased thr

184 also evaluated how different drug regimens (polypharmacy/monotherapy) influenced activities in young

185 tion, emotional health, comorbid conditions, polypharmacy, nutrition, and social support.

186 Morbidity and subsequent polypharmacy occurred more frequently among the patients

187 cal evidence suggests that one aspect of the polypharmacy of CBD is that it modulates brain excitator

188 soned adjuvant design permits one to perform polypharmacy on bacteria by not only providing greater i

189 Polypharmacy or a history of radiation to the head and n

190 19 sites) were randomly assigned to stay on polypharmacy or switch to monotherapy by discontinuing o

191 sks and benefits of staying on antipsychotic polypharmacy or switching to monotherapy.

192 able to dissociate the influence of maternal polypharmacy or the environment from direct effects of i

193 yperpolypharmacy compared with those without polypharmacy (OR = 3.46; 95% CI = 1.32-9.12).

194 imorbidity (OR, 1.50; 95% CI, 1.47-1.53) and polypharmacy (OR, 1.82; 95% CI, 1.78-1.85) at presentati

195 se with polypharmacy and 4% of those without polypharmacy (p < 0.0001) and at least one complication

196 er, persistent comorbidity burden and rising polypharmacy-particularly among women-highlight the need

197 The unintended consequences of polypharmacy pose significant risks to older adults.

198 ith hospitalization were eating problems and polypharmacy (positive predictive value: 17.9%; sensitiv

199 Despite potential harm that can result from polypharmacy, real-world data on polypharmacy in the set

200 admission (eg, advanced age, multimorbidity, polypharmacy, recent hospitalization), features of the i

201 ed little evidence of an association between polypharmacy-related interventions and reduced important

202 The study of polypharmacy-related interventions has increased substan

203 ), finding wide variation in the adoption of polypharmacy-related interventions.

204 orbidity incidence was largely stable, while polypharmacy rose, especially in older adults and women.

205 elative risk [RR], 0.52; 95% CI, 0.35-0.77), polypharmacy (RR, 0.41; 95% CI, 0.23-0.74), and disabili

206 The efficacy of polypharmacy showed additivity when gentamicin or ceftaz

207 can achieve state-of-the-art performance on polypharmacy side effect prediction, with our best model

208 : prediction of drug-target interactions and polypharmacy side effects.

209 nal dependence, organ function, comorbidity, polypharmacy, social support, cognitive and/or psychosoc

210 Given the rising rates of polypharmacy that lead to increased concomitant use of m

211 gents identified to date display significant polypharmacy that severely compromises interpretation of

212 g those who met the criterion for CNS-active polypharmacy, the median number of polypharmacy-days was

213 g patients who had used both monotherapy and polypharmacy, the risk of nonpsychiatric hospitalization

214 older people living with multimorbidity and polypharmacy: the TAILOR evidence synthesis.

215 rther inform considerations of age, sex, and polypharmacy to optimize quality use of medicines.

216 spitalization was significantly lower during polypharmacy use at all total dosage categories above 1.

217 Comparison of any polypharmacy use with any monotherapy use showed no sign

218 The prevalence of polypharmacy (use of >/=5 prescription drugs) increased

219 is, neuropathy pain, substance use disorder, polypharmacy, (use of) benzodiazepines, gabapentinoids,

220 nd association of OD with multimorbidity and polypharmacy using real-life data to complete this spect

221 a retrospective standardized chart review of polypharmacy visits during October and November 2022.

222 Our review included 84 polypharmacy visits; the average patient age was 80.

223 revalence of multimorbidity was 69.3% and of polypharmacy was 46.6%.

224 ts with GERD, age-standardized prevalence of polypharmacy was 9.5% (95% CI: 7.5%, 11.6%) in males, an

225 Hence, polypharmacy was associated with a higher risk of hospit

226 Furthermore, polypharmacy was associated with greater risk of hospita

227 Polypharmacy was associated with lower risk of gaining A

228 Polypharmacy was associated with membership in class 2 (

229 ge, mixed-sex cohort of PWH aged >=40 years, polypharmacy was associated with slow gait speed and rec

230 7% male; mean [SD] age, 14.45 [9.40] years), polypharmacy was common, ranging from 28.6% to 31.5%.

231 Polypharmacy was commonplace (up to 43 medications per d

232 Antipsychotic polypharmacy was compared with monotherapy in seven dosa

233 Polypharmacy was defined as the use of >=5 non-HIV medic

234 Polypharmacy was higher in PLWH (32.94%) than individual

235 Polypharmacy was more common in women (30%) than men (23

236 Polypharmacy was more common in women than men in both P

237 Polypharmacy was more common in women than men in both P

238 Polypharmacy was more frequent among PLWH across all age

239 The increasing trend of psychotropic polypharmacy was mostly similar across visits by differe

240 Although polypharmacy was not associated with higher risk of stro

241 Polypharmacy was significantly higher in PLWH (32.94%) t

242 Comorbidities and polypharmacy were important predictors of COT in Medicai

243 At 24 months, patients with polypharmacy were more likely to be diagnosed with pneum

244 creases in overall prescription drug use and polypharmacy were observed.

245 h 6, 86% (N=48) of those assigned to stay on polypharmacy were still taking both medications, whereas

246 data showing high rates of comorbidities and polypharmacy, which led to the establishment of a specia

247 morbidities and the associated challenges of polypharmacy, while also attending to HIV-specific healt

248 morbidities and the associated challenges of polypharmacy, while not neglecting HIV-related health co

249 VID-19 affects people with comorbidities and polypharmacy who could benefit from therapy, but prescri

250 g continuous monitoring, we demonstrated how polypharmacy with high Drug Burden Index (DBI-cumulative

251 rapy for individuals receiving antipsychotic polypharmacy, with the caveat that patients should be fr

252 examine patterns and trends in psychotropic polypharmacy within nationally representative samples of

253 use of monotherapy instead of antipsychotic polypharmacy without any existing evidence on the safety